MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

Search

MacroGenics Inc

Затворен

СекторЗдравеопазване

1.77 3.51

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.71

Максимум

1.82

Ключови измерители

By Trading Economics

Приходи

4.8M

-36M

Продажби

9M

22M

Марж на печалбата

-162.992

Служители

341

EBITDA

5.7M

-33M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+113.07% upside

Дивиденти

By Dow Jones

Следващи печалби

4.11.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

18M

111M

Предишно отваряне

-1.74

Предишно затваряне

1.77

Настроения в новините

By Acuity

27%

73%

86 / 371 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Neutral Evidence

MacroGenics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

7.10.2025 г., 16:58 ч. UTC

Печалби

BMW Trims 2025 View, Citing Weaker Performance in China

7.10.2025 г., 23:43 ч. UTC

Пазарно говорене

Nikkei May Trade Rangebound; Takaichi's Policy Steps in Focus -- Market Talk

7.10.2025 г., 23:36 ч. UTC

Пазарно говорене

Gold Edges Higher, Supported by Possible Hedging Demand -- Market Talk

7.10.2025 г., 23:19 ч. UTC

Пазарно говорене

Veem Can Secure More Defense Deals Following Northrop Grumman Win -- Market Talk

7.10.2025 г., 22:50 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

7.10.2025 г., 22:50 ч. UTC

Пазарно говорене

RBNZ Should Take the Option of a Bigger Cut -- Market Talk

7.10.2025 г., 22:40 ч. UTC

Пазарно говорене

South32's Alaskan Project Seen Starting Sooner, Worth More After U.S. Deal -- Market Talk

7.10.2025 г., 21:56 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

7.10.2025 г., 21:56 ч. UTC

Пазарно говорене

Australia Shares Set to Start Day Roughly Flat -- Market Talk

7.10.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

7.10.2025 г., 20:44 ч. UTC

Горещи акции

Stocks to Watch Tuesday Recap: Oracle, Dell, Trilogy Metals -- WSJ

7.10.2025 г., 19:42 ч. UTC

Пазарно говорене

Treasury Yields Fall as Data Blackout Continues -- Market Talk

7.10.2025 г., 19:23 ч. UTC

Придобивния, сливания и поглъщания

Private-Equity Stocks Have Gotten Crushed. J.P. Morgan Says This One Is a Buy. -- Barrons.com

7.10.2025 г., 19:07 ч. UTC

Пазарно говорене

Oil Futures Settle Mixed With Higher OPEC+ Supply in View -- Market Talk

7.10.2025 г., 19:02 ч. UTC

Пазарно говорене

U.S. Natural Gas Posts Back-to-Back Gains -- Market Talk

7.10.2025 г., 16:20 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

7.10.2025 г., 16:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

7.10.2025 г., 16:20 ч. UTC

Пазарно говорене

Home Depot Extended Pro Desk Hours Could Drive Sales Growth -- Market Talk

7.10.2025 г., 16:15 ч. UTC

Пазарно говорене

AMD's OpenAI Deal Resets Competitive Landscape for Chips -- Market Talk

7.10.2025 г., 16:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

7.10.2025 г., 15:37 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

7.10.2025 г., 15:37 ч. UTC

Пазарно говорене

Markets for Canadian Aluminum Open Up Beyond U.S. -- Market Talk

7.10.2025 г., 15:33 ч. UTC

Пазарно говорене

Gold Rise Tied to Lower Confidence in Dollar Assets -- Market Talk

7.10.2025 г., 15:25 ч. UTC

Пазарно говорене

Canadian Mining Stocks Rally on U.S. Defense Dept. Deal -- Market Talk

7.10.2025 г., 15:15 ч. UTC

Пазарно говорене

Investors Look to Gold, Bitcoin as Traditional Correlations Break Down -- Market Talk

7.10.2025 г., 15:04 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

7.10.2025 г., 15:04 ч. UTC

Пазарно говорене

Canadian Aluminum Exports Squeezed by Tariffs -- Market Talk

7.10.2025 г., 14:56 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

7.10.2025 г., 14:56 ч. UTC

Пазарно говорене

U.S. Government Shutdown May Impact Release of Canadian Trade Data -- Market Talk

7.10.2025 г., 14:52 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Tesla, AMD, Ford, Dell, IBM, AppLovin, Trilogy Metals, Aehr, and More -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

MacroGenics Inc Прогноза

Ценова цел

By TipRanks

113.07% нагоре

12-месечна прогноза

Среден 3.75 USD  113.07%

Висок 5 USD

Нисък 3 USD

Според 6 анализатори от Wall Street, предложили 12-месечна ценова цел за MacroGenics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

6 ratings

3

Купи

3

Задържане

0

Продай

Техническа оценка

By Trading Central

1.47 / 1.64Подкрепа & съпротива

Краткосрочен план

Neutral Evidence

Средносрочен план

Bullish Evidence

Дългосрочен план

Bearish Evidence

Настроение

By Acuity

86 / 371 Класиране в Здравеопазване

Настроения в новините

Бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Над средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно MacroGenics Inc

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.
help-icon Live chat